Canaccord Genuity Maintains Buy on Taysha Gene Therapies, Raises Price Target to $17
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Whitney Ijem maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $14 to $17.
Canaccord Genuity analyst Whitney Ijem maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $14 to $17.